Physician profile
Seva Milov
NPI 1205022746
$2,670.48
in general payments reported to CMS, 2019-2025
27 companies · $588 in 2025
The $588 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $792 · 2021: $298 · 2022: $15.35 · 2023: $368 · 2024: $237 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $687.31 | 2020 | |
| Baxter Healthcare | $642.78 | 2021-2025 | Tisseel, Perclot |
| Abbvie INC. | $335.67 | 2019-2023 | |
| Intuitive Surgical, INC. | $277.98 | 2019-2023 | Da Vinci Surgical System |
| Sumitomo Pharma America, INC. | $78.97 | 2023-2024 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $76.57 | 2024-2025 | Veozah |
| Sage Therapeutics, LLC | $68.85 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $47.47 | 2019-2023 | Injectafer |
| Davol INC. | $43.35 | 2025 | Arista |
| Minerva Surgical, INC | $42.10 | 2024-2025 | |
| Hologic Sales and Service, LLC | $38.85 | 2022-2025 | Novasure |
| Exeltis, USA INC. | $31.34 | 2019-2024 | Slynd |
| Vertex Pharmaceuticals Incorporated | $30.94 | 2025 | |
| Lupin INC. | $30.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.10 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $25.19 | 2023 | Axonics |
| Coopersurgical, INC. | $23.22 | 2025 | Sos |
| Boston Scientific Corporation | $21.83 | 2025 | Bulkamid |
| Bard Access Systems, INC. | $19.61 | 2019 | |
| Meditrina | $18.50 | 2023 | |
| Smith+Nephew, INC. | $17.26 | 2020 | |
| Organon LLC | $16.21 | 2023 | Nexplanon |
| Olympus America INC. | $15.22 | 2025 | Olympus |
| Shield Therapeutics INC | $14.84 | 2025 | |
| Supernus Pharmaceuticals, INC. | $13.65 | 2025 | Qelbree |
| Millicent US INC | $11.91 | 2019 | |
| Allergan, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seva Milov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.